PDF(Sci-hub)
Abstract：
Tick-borne encephalitis (TBE) virus, which is usually divided into European, Far Eastern and Siberian subtypes, is a serious public health problem in several European and Asian countries. Vaccination is the most effective measure to prevent TBE; cross-subtype protection elicited by the TBE vaccines is biologically plausible since all TBE virus subtypes are closely related. This manuscript systematically explores available data on the cross-subtype immunogenicity elicited by the currently available Western vaccines based on the European subtype. Completed immunization course of 3 doses of both Western vaccines determined very high seroconversion/seropositivity rates against both Far Eastern and Siberian subtypes among previously flavivirus-naïve subjects. All but one study found no statistically significant difference in titers of neutralizing antibodies against strains belonging to homologous and heterologous subtypes. Pooled analysis of randomized controlled trials on head-to-head comparison of immunogenicity of Western and Russian TBE vaccines did not reveal differences in seroconversion rates against Far Eastern isolates in either hemagglutination inhibition (risk ratio = 0.98, p = 0.83) or enzyme-linked immunosorbent (risk ratio = 0.95, p = 0.44) assays after 2 vaccine doses. This suggests that, in regions where a heterogeneous TBE virus population circulates, vaccines based on the European subtype may be used alongside vaccines based on the Far Eastern subtype. Studies on the field effectiveness of TBE vaccines and investigation of vaccination failures, especially in countries where different subtypes co-circulate, will further elucidate TBE vaccination-induced cross-subtype protection.
摘要：
蜱传脑炎（TBE）病毒，通常分为欧洲，远东和西伯利亚亚型，在几个欧洲和亚洲国家是一个严重的公共卫生问题。疫苗接种是预防TBE的最有效措施；由于所有TBE病毒亚型都密切相关，因此TBE疫苗引起的交叉亚型保护在生物学上似乎是合理的。该手稿系统地探索了基于欧洲亚型的当前可用的西方疫苗引起的交叉亚型免疫原性的可用数据。在先前未感染黄病毒的受试者中，完成3剂两种Western疫苗的免疫过程确定了针对远东和西伯利亚亚型的非常高的血清转化/血清阳性率。除一项研究外，所有研究均未发现针对属于同源和异源亚型的菌株的中和抗体的滴度具有统计学上的显着差异。对西方和俄罗斯TBE疫苗的免疫原性进行头对头比较的随机对照试验的汇总分析未发现在2次疫苗剂量后的血凝抑制（风险比=0.98，p=0.83）或酶联免疫吸附（风险比=0.95，p=0.44）测定中，针对远东分离株的血清转化率存在差异。这表明,在异质性TBE病毒种群传播的地区，基于欧洲亚型的疫苗可以与基于远东亚型的疫苗一起使用。TBE疫苗的现场有效性研究和疫苗接种失败的调查，特别是在不同亚型共同传播的国家，将进一步阐明TBE疫苗接种诱导的交叉亚型保护。
